NCT02914613View on ClinicalTrials.gov

Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

August 24, 2016

Primary Completion Date

May 16, 2017

Study Completion Date

May 16, 2017

Conditions
Diabetic Macular Edema
Interventions
DRUG

SF0166 Topical Ophthalmic Solution

Trial Locations (6)

33880

Center for Retina and Macular Disease, Winter Haven

77030

Retina Consultants of Houston, Houston

90211

Retina-Vitreous Associates Medical Group, Beverly Hills

90301

United Medical Research Institute, Inglewood

95670

Martel Eye Medical Group, Rancho Cordova

02114

Ophthalmic Consultants of Boston, Boston

Sponsors
All Listed Sponsors
lead

OcuTerra Therapeutics, Inc.

INDUSTRY

NCT02914613 - Safety and Exploratory Efficacy Study of SF0166 for the Treatment of Diabetic Macular Edema (DME) | Biotech Hunter | Biotech Hunter